Trends in New Use of Disease‐Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022

Documenti analoghi

• Sex Differences in B Cells From the Joints of Children With Oligoarticular Juvenile Idiopathic Arthritis
  di: Ki Pui Lam, et al.
  Pubblicazione: (2025)
• Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders
  di: Yoshihiko Hoshida, et al.
  Pubblicazione: (2024)
• Associations Between Changes in Pain Sensitization and Disease Activity Following Disease‐Modifying Antirheumatic Drug Therapy in Established Rheumatoid Arthritis
  di: Burcu Aydemir, et al.
  Pubblicazione: (2025)
• Incidence and Genetic Risk of Juvenile Idiopathic Arthritis in Norway by Latitude
  di: Sigrid V. Hestetun, et al.
  Pubblicazione: (2024)
• Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic Arthritis
  di: Viola Pitkänen, et al.
  Pubblicazione: (2025)